Symbols

ACRS

Aclaris Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 7

Bearish signal 1

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

MACD Golden Cross

Ample Liquidity

High Gross Profit Margin

Gap Up

Revenue Beats Expectation

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ACRS

Aclaris Therapeutics, Inc.

A clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases

Industry

Pharmaceutical

Established Date

Listing Date

10/07/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.aclaristx.com

Security Type

Common stock

Office address

701 Lee Road, Suite 103, Wayne, PA 19087

Business

Introduction

Aclaris Therapeutics, Inc., was founded in July 2012 in Delaware, USA. The company is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune inflammatory diseases.

Company Financials

EPS

ACRS has released its 2025 Q4 earnings. EPS was reported at -0.16, versus the expected -0.15, missing expectations. The chart below visualizes how ACRS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ACRS has released its 2025 Q4 earnings report, with revenue of 1.29M, reflecting a YoY change of -85.94%, and net profit of -19.80M, showing a YoY change of 79.50%. The Sankey diagram below clearly presents ACRS's revenue sources and cost distribution.